Barchart on MSN2d
Are Wall Street Analysts Predicting Cardinal Health Stock Will Climb or Sink?
Dublin, Ohio-based Cardinal Health, Inc. (CAH) manufactures and distributes pharmaceuticals, medical & laboratory products, ...
With 88% ownership in Cardinal Health, Inc. (NYSE:CAH), institutional investors have a lot riding on the business
Key Insights Given the large stake in the stock by institutions, Cardinal Health's stock price might be vulnerable ...
Zacks.com on MSN12d
CAH Q2 Earnings and Sales Beat Estimates, 2025 EPS View Raised
Cardinal Health, Inc. CAH reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.93, which beat the ...
FiercePharma2d
With Teva competition heating up, Neurocrine's tame Ingrezza forecast spooks investors
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...
Cardinal Health Inc (CAH) Q2 2025 Earnings Call Highlights: Strong Pharma Growth Amid Revenue ...
Cardinal Health Inc (CAH) raises EPS guidance despite a 4% revenue decline, driven by robust pharmaceutical segment ...
Cardinal Health raised to buy by Jefferies
Jefferies has upgraded Cardinal Health (CAH) to buy from hold, citing management's emerging EPS track record. Read more here.
Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval
Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...
Cardinal Health upgraded to Buy from Hold at Jefferies
Jefferies analyst Brian Tanquilut upgraded Cardinal Health (CAH) to Buy from Hold with a price target of $150, up from $140. The firm thinks ...
Nasdaq12d
CAH Q2 Earnings and Sales Beat Estimates, 2025 EPS View Raised
Cardinal Health, Inc. CAH reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.93, which beat the Zacks Consensus Estimate of $1.75 by 10.3%. The bottom line also improved 2 ...